Biocon receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biocon Ltd. (BION)
Track the Biocon share price today and view real-time BION share price data, including charts, technicals, and key financials. View the BION premarket stock price ahead of the market session or assess the after hours quote. Explore BION stock price movements, trading volume, and market activity across the NSE exchange.
What Is the Biocon Stock Price Today?
The Biocon stock price today is 436.25.
What Is the Stock Symbol for Biocon?
The stock symbol for Biocon is ""BION.""
What Stock Exchange Does Biocon Trade On?
Biocon is listed and trades on the NSE stock exchange.
Is Biocon a Good Stock to Buy?
Determining whether Biocon or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BION quote. (ISIN: INE376G01013)
What Is the Biocon Stock Price Today?
The Biocon stock price today is 436.25.
What Is the Stock Symbol for Biocon?
The stock symbol for Biocon is ""BION.""
What Stock Exchange Does Biocon Trade On?
Biocon is listed and trades on the NSE stock exchange.
Is Biocon a Good Stock to Buy?
Determining whether Biocon or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BION quote. (ISIN: INE376G01013)
436.25
+2.60(+0.60%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
434.05
437.55
52 wk Range
331.00
447.15
Earnings results expected in 10 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
434.05437.55
52 wk Range
331.00447.15
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.11%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.11%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
BION Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
423.70
Downside
-2.88%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Biocon receives Investment Bank Analyst Rating Update- Investing.com
Pro
Biocon receives Investment Bank Analyst Rating Update- Investing.com
Pro
Biocon receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Biocon receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Biocon receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Biocon receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Biocon launches denosumab biosimilars in US market- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
11 Buy
3 Hold
6 Sell
Ratings:
20 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 423.70
(-2.88% Downside)
Earnings
Latest Release
07/05/2026
EPS / Forecast
1.20 / 1.37
Revenue / Forecast
45.17B / 45.41B
Compare BION to Peers and Sector
Metrics to compare | BION | Peers Peers - average of corresponding metrics from companies closely matching BION: THEMISMED, SYNGENE, GLENMARK, AKUMS, WOCKPHARMA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIONPeersSector |
|---|---|---|---|---|
P/E Ratio | 182.1x | 36.6x | −0.4x | |
PEG Ratio | −2.75 | 0.30 | 0.00 | |
Price/Book | 2.1x | 3.7x | 2.6x | |
Price / LTM Sales | 4.1x | 4.1x | 2.9x | |
Upside (Analyst Target) | −2.6% | 4.7% | 58.0% | |
Fair Value Upside | Unlock | −0.8% | 9.5% | Unlock |
Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Biocon (BION) Stock Price Today?
The Biocon stock price today is 436.25 INR.
What Stock Exchange Does Biocon Trade On?
Biocon is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Biocon?
The stock symbol for Biocon is "BION."
Does Biocon Pay Dividends? What’s The Current Dividend Yield?
The Biocon dividend yield is 0.11%.
What Is the Biocon Market Cap?
As of today, Biocon market cap is 706.51B INR.
What Is Biocon's Earnings Per Share (TTM)?
The Biocon EPS (TTM) is 2.82.
When Is the Next Biocon Earnings Date?
Biocon will release its next earnings report on 06/08/2026.
From a Technical Analysis Perspective, Is BION a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Biocon Stock Split?
Biocon has split 3 times.
How Many Employees Does Biocon Have?
Biocon has 16447 employees.
What is the current trading status of Biocon (BION)?
As of 27/07/2026, Biocon (BION) is trading at a price of 436.25 INR, with a previous close of 433.65 INR. The stock has fluctuated within a day range of 434.05 INR to 437.55 INR, while its 52-week range spans from 331.00 INR to 447.15 INR.
What Is Biocon (BION) Price Target According to Analysts?
The average 12-month price target for Biocon is 423.70 INR, with a high estimate of 506 INR and a low estimate of 290 INR. 11 analysts recommend buying the stock, while 6 suggest selling, leading to an overall rating of Buy. The stock has an -2.88% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.